Fifth Third Bancorp
MLYS icon

Fifth Third Bancorp’s Mineralys Therapeutics MLYS Stock Holding History

Fifth Third Bancorp’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.2K Buy
+784
New +$23K ﹤0.01% 3475
2025
Q3 		– Sell
-61
Closed -$825 – 2734
2025
Q2 		$825 Buy
+61
New +$884 ﹤0.01% 2450

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Fifth Third Bancorp's MLYS Position: Q1 2026 in Review

Fifth Third Bancorp opened a new position in Mineralys Therapeutics (MLYS) in Q1 2026: 784 shares worth $21.2K. The stake represents ﹤0.01% of the portfolio and ranks #3475 among its holdings. This is a return to the name: Fifth Third Bancorp previously reported a position in MLYS as recently as Q2 2025.

Fifth Third Bancorp first reported a position in MLYS in Q2 2025 and has held it in 2 quarters since. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Fifth Third Bancorp held 784 shares of Mineralys Therapeutics worth $21.2K as of Q1 2026.
  • Mineralys Therapeutics was a new Fifth Third Bancorp position in Q1 2026.
  • Mineralys Therapeutics made up ﹤0.01% of Fifth Third Bancorp's portfolio in Q1 2026, its #3475 holding.
  • Fifth Third Bancorp first reported a position in Mineralys Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Fifth Third Bancorp's 13F filing for Q1 2026, filed 1 May 2026.